XY03-EA
/ Shijiazhuang Yiling Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
January 03, 2025
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
(clinicaltrials.gov)
- P2/3 | N=360 | Enrolling by invitation | Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd
New P2/3 trial • Cardiovascular • Ischemic stroke
June 22, 2023
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
(clinicaltrials.gov)
- P2 | N=420 | Enrolling by invitation | Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd | Not yet recruiting ➔ Enrolling by invitation | Trial completion date: Aug 2024 ➔ Dec 2023 | Trial primary completion date: Aug 2024 ➔ Dec 2023
Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke
August 25, 2022
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
(clinicaltrials.gov)
- P2 | N=420 | Not yet recruiting | Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd
New P2 trial • Cardiovascular • Ischemic stroke
1 to 3
Of
3
Go to page
1